IRAK4 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "IRAK4" in English language version.

refsWebsite

Global rank English rank

29nih.gov

4^th place

20doi.org

2^nd place

7semanticscholar.org

11^th place

8^th place

5harvard.edu

18^th place

17^th place

2ensembl.org

1,626^th place

1,007^th place

1prnewswire.com

406^th place

258^th place

doi.org (Global: 2^nd place; English: 2^nd place)

Martin M, Böl GF, Eriksson A, Resch K, Brigelius-Flohé R (July 1994). "Interleukin-1-induced activation of a protein kinase co-precipitating with the type I interleukin-1 receptor in T cells". European Journal of Immunology. 24 (7): 1566–1571. doi:10.1002/eji.1830240717. PMID 8026518. S2CID 25609420.
Cao Z, Henzel WJ, Gao X (February 1996). "IRAK: a kinase associated with the interleukin-1 receptor". Science. 271 (5252): 1128–1131. Bibcode:1996Sci...271.1128C. doi:10.1126/science.271.5252.1128. PMID 8599092. S2CID 42977425.
Li S, Strelow A, Fontana EJ, Wesche H (April 2002). "IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase". Proceedings of the National Academy of Sciences of the United States of America. 99 (8): 5567–5572. Bibcode:2002PNAS...99.5567L. doi:10.1073/pnas.082100399. PMC 122810. PMID 11960013.
Kawagoe T, Sato S, Jung A, Yamamoto M, Matsui K, Kato H, et al. (May 2007). "Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling". The Journal of Experimental Medicine. 204 (5): 1013–1024. doi:10.1084/jem.20061523. PMC 2118579. PMID 17485511.
Wang Z, Liu J, Sudom A, Ayres M, Li S, Wesche H, et al. (December 2006). "Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper". Structure. 14 (12): 1835–1844. doi:10.1016/j.str.2006.11.001. PMID 17161373.
Kuglstatter A, Villaseñor AG, Shaw D, Lee SW, Tsing S, Niu L, et al. (March 2007). "Cutting Edge: IL-1 receptor-associated kinase 4 structures reveal novel features and multiple conformations". Journal of Immunology. 178 (5): 2641–2645. doi:10.4049/jimmunol.178.5.2641. PMID 17312103.
Cheng H, Addona T, Keshishian H, Dahlstrand E, Lu C, Dorsch M, et al. (January 2007). "Regulation of IRAK-4 kinase activity via autophosphorylation within its activation loop". Biochemical and Biophysical Research Communications. 352 (3): 609–616. Bibcode:2007BBRC..352..609C. doi:10.1016/j.bbrc.2006.11.068. PMID 17141195.
Ferrao R, Zhou H, Shan Y, Liu Q, Li Q, Shaw DE, et al. (September 2014). "IRAK4 dimerization and trans-autophosphorylation are induced by Myddosome assembly". Molecular Cell. 55 (6): 891–903. doi:10.1016/j.molcel.2014.08.006. PMC 4169746. PMID 25201411.
Xu Q, Malecka KL, Fink L, Jordan EJ, Duffy E, Kolander S, et al. (December 2015). "Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases". Science Signaling. 8 (405): rs13. doi:10.1126/scisignal.aaa6711. PMC 4766099. PMID 26628682.
Ku CL, Yang K, Bustamante J, Puel A, von Bernuth H, Santos OF, et al. (February 2005). "Inherited disorders of human Toll-like receptor signaling: immunological implications". Immunological Reviews. 203: 10–20. doi:10.1111/j.0105-2896.2005.00235.x. PMID 15661018. S2CID 21786295.
Wang Z, Wesche H, Stevens T, Walker N, Yeh WC (1 January 2009). "IRAK-4 inhibitors for inflammation". Current Topics in Medicinal Chemistry. 9 (8): 724–737. doi:10.2174/156802609789044407. PMC 3182414. PMID 19689377.
Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, et al. (April 2002). "Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4". Nature. 416 (6882): 750–756. Bibcode:2002Natur.416..750S. doi:10.1038/nature736. PMID 11923871. S2CID 4428621.
Chaudhary D, Robinson S, Romero DL (January 2015). "Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders". Journal of Medicinal Chemistry. 58 (1): 96–110. doi:10.1021/jm5016044. PMID 25479567.
Sun J, Wiklund F, Hsu FC, Bälter K, Zheng SL, Johansson JE, et al. (March 2006). "Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk". Cancer Epidemiology, Biomarkers & Prevention. 15 (3): 480–485. doi:10.1158/1055-9965.EPI-05-0645. PMID 16537705. S2CID 25190194.
Srivastava R, Geng D, Liu Y, Zheng L, Li Z, Joseph MA, et al. (December 2012). "Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4". Cancer Research. 72 (23): 6209–6216. doi:10.1158/0008-5472.CAN-12-0337. PMC 3677596. PMID 23041547.
Somani V, Zhang D, Dodhiawala PB, Lander VE, Liu X, Kang LI, et al. (March 2022). "IRAK4 signaling drives resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma". Gastroenterology. 162 (7): 2047–2062. doi:10.1053/j.gastro.2022.02.035. PMC 9387774. PMID 35271824.
Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, et al. (March 2003). "Pyogenic bacterial infections in humans with IRAK-4 deficiency". Science. 299 (5615): 2076–2079. Bibcode:2003Sci...299.2076P. doi:10.1126/science.1081902. PMID 12637671. S2CID 22438404.
Ku CL, von Bernuth H, Picard C, Zhang SY, Chang HH, Yang K, et al. (October 2007). "Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity". The Journal of Experimental Medicine. 204 (10): 2407–2422. doi:10.1084/jem.20070628. PMC 2118442. PMID 17893200.
Feng Y, et al. Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer. Acta Pharmaceutica Sinica B 2024; 14(12): 5091-5105 doi:10.1016/j.apsb.2024.09.008
Mullard A (November 2020). "IRAK4 degrader to take on innate immunity". Nature Biotechnology. 38 (11): 1221–1223. doi:10.1038/s41587-020-0724-8. PMID 33144727. S2CID 226249972.

ensembl.org (Global: 1,626^th place; English: 1,007^th place)

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000198001 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000059883 – Ensembl, May 2017

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Cao Z, Henzel WJ, Gao X (February 1996). "IRAK: a kinase associated with the interleukin-1 receptor". Science. 271 (5252): 1128–1131. Bibcode:1996Sci...271.1128C. doi:10.1126/science.271.5252.1128. PMID 8599092. S2CID 42977425.
Li S, Strelow A, Fontana EJ, Wesche H (April 2002). "IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase". Proceedings of the National Academy of Sciences of the United States of America. 99 (8): 5567–5572. Bibcode:2002PNAS...99.5567L. doi:10.1073/pnas.082100399. PMC 122810. PMID 11960013.
Cheng H, Addona T, Keshishian H, Dahlstrand E, Lu C, Dorsch M, et al. (January 2007). "Regulation of IRAK-4 kinase activity via autophosphorylation within its activation loop". Biochemical and Biophysical Research Communications. 352 (3): 609–616. Bibcode:2007BBRC..352..609C. doi:10.1016/j.bbrc.2006.11.068. PMID 17141195.
Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, et al. (April 2002). "Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4". Nature. 416 (6882): 750–756. Bibcode:2002Natur.416..750S. doi:10.1038/nature736. PMID 11923871. S2CID 4428621.
Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, et al. (March 2003). "Pyogenic bacterial infections in humans with IRAK-4 deficiency". Science. 299 (5615): 2076–2079. Bibcode:2003Sci...299.2076P. doi:10.1126/science.1081902. PMID 12637671. S2CID 22438404.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Martin M, Böl GF, Eriksson A, Resch K, Brigelius-Flohé R (July 1994). "Interleukin-1-induced activation of a protein kinase co-precipitating with the type I interleukin-1 receptor in T cells". European Journal of Immunology. 24 (7): 1566–1571. doi:10.1002/eji.1830240717. PMID 8026518. S2CID 25609420.
Cao Z, Henzel WJ, Gao X (February 1996). "IRAK: a kinase associated with the interleukin-1 receptor". Science. 271 (5252): 1128–1131. Bibcode:1996Sci...271.1128C. doi:10.1126/science.271.5252.1128. PMID 8599092. S2CID 42977425.
Li S, Strelow A, Fontana EJ, Wesche H (April 2002). "IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase". Proceedings of the National Academy of Sciences of the United States of America. 99 (8): 5567–5572. Bibcode:2002PNAS...99.5567L. doi:10.1073/pnas.082100399. PMC 122810. PMID 11960013.
Kawagoe T, Sato S, Jung A, Yamamoto M, Matsui K, Kato H, et al. (May 2007). "Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling". The Journal of Experimental Medicine. 204 (5): 1013–1024. doi:10.1084/jem.20061523. PMC 2118579. PMID 17485511.
Wang Z, Liu J, Sudom A, Ayres M, Li S, Wesche H, et al. (December 2006). "Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper". Structure. 14 (12): 1835–1844. doi:10.1016/j.str.2006.11.001. PMID 17161373.
Kuglstatter A, Villaseñor AG, Shaw D, Lee SW, Tsing S, Niu L, et al. (March 2007). "Cutting Edge: IL-1 receptor-associated kinase 4 structures reveal novel features and multiple conformations". Journal of Immunology. 178 (5): 2641–2645. doi:10.4049/jimmunol.178.5.2641. PMID 17312103.
Cheng H, Addona T, Keshishian H, Dahlstrand E, Lu C, Dorsch M, et al. (January 2007). "Regulation of IRAK-4 kinase activity via autophosphorylation within its activation loop". Biochemical and Biophysical Research Communications. 352 (3): 609–616. Bibcode:2007BBRC..352..609C. doi:10.1016/j.bbrc.2006.11.068. PMID 17141195.
Ferrao R, Zhou H, Shan Y, Liu Q, Li Q, Shaw DE, et al. (September 2014). "IRAK4 dimerization and trans-autophosphorylation are induced by Myddosome assembly". Molecular Cell. 55 (6): 891–903. doi:10.1016/j.molcel.2014.08.006. PMC 4169746. PMID 25201411.
Xu Q, Malecka KL, Fink L, Jordan EJ, Duffy E, Kolander S, et al. (December 2015). "Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases". Science Signaling. 8 (405): rs13. doi:10.1126/scisignal.aaa6711. PMC 4766099. PMID 26628682.
Ku CL, Yang K, Bustamante J, Puel A, von Bernuth H, Santos OF, et al. (February 2005). "Inherited disorders of human Toll-like receptor signaling: immunological implications". Immunological Reviews. 203: 10–20. doi:10.1111/j.0105-2896.2005.00235.x. PMID 15661018. S2CID 21786295.
Wang Z, Wesche H, Stevens T, Walker N, Yeh WC (1 January 2009). "IRAK-4 inhibitors for inflammation". Current Topics in Medicinal Chemistry. 9 (8): 724–737. doi:10.2174/156802609789044407. PMC 3182414. PMID 19689377.
Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, et al. (April 2002). "Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4". Nature. 416 (6882): 750–756. Bibcode:2002Natur.416..750S. doi:10.1038/nature736. PMID 11923871. S2CID 4428621.
Chaudhary D, Robinson S, Romero DL (January 2015). "Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders". Journal of Medicinal Chemistry. 58 (1): 96–110. doi:10.1021/jm5016044. PMID 25479567.
Sun J, Wiklund F, Hsu FC, Bälter K, Zheng SL, Johansson JE, et al. (March 2006). "Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk". Cancer Epidemiology, Biomarkers & Prevention. 15 (3): 480–485. doi:10.1158/1055-9965.EPI-05-0645. PMID 16537705. S2CID 25190194.
Srivastava R, Geng D, Liu Y, Zheng L, Li Z, Joseph MA, et al. (December 2012). "Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4". Cancer Research. 72 (23): 6209–6216. doi:10.1158/0008-5472.CAN-12-0337. PMC 3677596. PMID 23041547.
Somani V, Zhang D, Dodhiawala PB, Lander VE, Liu X, Kang LI, et al. (March 2022). "IRAK4 signaling drives resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma". Gastroenterology. 162 (7): 2047–2062. doi:10.1053/j.gastro.2022.02.035. PMC 9387774. PMID 35271824.
Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, et al. (March 2003). "Pyogenic bacterial infections in humans with IRAK-4 deficiency". Science. 299 (5615): 2076–2079. Bibcode:2003Sci...299.2076P. doi:10.1126/science.1081902. PMID 12637671. S2CID 22438404.
Ku CL, von Bernuth H, Picard C, Zhang SY, Chang HH, Yang K, et al. (October 2007). "Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity". The Journal of Experimental Medicine. 204 (10): 2407–2422. doi:10.1084/jem.20070628. PMC 2118442. PMID 17893200.
Mullard A (November 2020). "IRAK4 degrader to take on innate immunity". Nature Biotechnology. 38 (11): 1221–1223. doi:10.1038/s41587-020-0724-8. PMID 33144727. S2CID 226249972.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Li S, Strelow A, Fontana EJ, Wesche H (April 2002). "IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase". Proceedings of the National Academy of Sciences of the United States of America. 99 (8): 5567–5572. Bibcode:2002PNAS...99.5567L. doi:10.1073/pnas.082100399. PMC 122810. PMID 11960013.
Kawagoe T, Sato S, Jung A, Yamamoto M, Matsui K, Kato H, et al. (May 2007). "Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling". The Journal of Experimental Medicine. 204 (5): 1013–1024. doi:10.1084/jem.20061523. PMC 2118579. PMID 17485511.
Ferrao R, Zhou H, Shan Y, Liu Q, Li Q, Shaw DE, et al. (September 2014). "IRAK4 dimerization and trans-autophosphorylation are induced by Myddosome assembly". Molecular Cell. 55 (6): 891–903. doi:10.1016/j.molcel.2014.08.006. PMC 4169746. PMID 25201411.
Xu Q, Malecka KL, Fink L, Jordan EJ, Duffy E, Kolander S, et al. (December 2015). "Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases". Science Signaling. 8 (405): rs13. doi:10.1126/scisignal.aaa6711. PMC 4766099. PMID 26628682.
Wang Z, Wesche H, Stevens T, Walker N, Yeh WC (1 January 2009). "IRAK-4 inhibitors for inflammation". Current Topics in Medicinal Chemistry. 9 (8): 724–737. doi:10.2174/156802609789044407. PMC 3182414. PMID 19689377.
Srivastava R, Geng D, Liu Y, Zheng L, Li Z, Joseph MA, et al. (December 2012). "Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4". Cancer Research. 72 (23): 6209–6216. doi:10.1158/0008-5472.CAN-12-0337. PMC 3677596. PMID 23041547.
Somani V, Zhang D, Dodhiawala PB, Lander VE, Liu X, Kang LI, et al. (March 2022). "IRAK4 signaling drives resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma". Gastroenterology. 162 (7): 2047–2062. doi:10.1053/j.gastro.2022.02.035. PMC 9387774. PMID 35271824.
Ku CL, von Bernuth H, Picard C, Zhang SY, Chang HH, Yang K, et al. (October 2007). "Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity". The Journal of Experimental Medicine. 204 (10): 2407–2422. doi:10.1084/jem.20070628. PMC 2118442. PMID 17893200.

prnewswire.com (Global: 406^th place; English: 258^th place)

Curis, Inc. (2019). "Curis Provides First-Ever Demonstration that Targeting IRAK4 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study". PR Newswire Association LLC.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Martin M, Böl GF, Eriksson A, Resch K, Brigelius-Flohé R (July 1994). "Interleukin-1-induced activation of a protein kinase co-precipitating with the type I interleukin-1 receptor in T cells". European Journal of Immunology. 24 (7): 1566–1571. doi:10.1002/eji.1830240717. PMID 8026518. S2CID 25609420.
Cao Z, Henzel WJ, Gao X (February 1996). "IRAK: a kinase associated with the interleukin-1 receptor". Science. 271 (5252): 1128–1131. Bibcode:1996Sci...271.1128C. doi:10.1126/science.271.5252.1128. PMID 8599092. S2CID 42977425.
Ku CL, Yang K, Bustamante J, Puel A, von Bernuth H, Santos OF, et al. (February 2005). "Inherited disorders of human Toll-like receptor signaling: immunological implications". Immunological Reviews. 203: 10–20. doi:10.1111/j.0105-2896.2005.00235.x. PMID 15661018. S2CID 21786295.
Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, et al. (April 2002). "Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4". Nature. 416 (6882): 750–756. Bibcode:2002Natur.416..750S. doi:10.1038/nature736. PMID 11923871. S2CID 4428621.
Sun J, Wiklund F, Hsu FC, Bälter K, Zheng SL, Johansson JE, et al. (March 2006). "Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk". Cancer Epidemiology, Biomarkers & Prevention. 15 (3): 480–485. doi:10.1158/1055-9965.EPI-05-0645. PMID 16537705. S2CID 25190194.
Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, et al. (March 2003). "Pyogenic bacterial infections in humans with IRAK-4 deficiency". Science. 299 (5615): 2076–2079. Bibcode:2003Sci...299.2076P. doi:10.1126/science.1081902. PMID 12637671. S2CID 22438404.
Mullard A (November 2020). "IRAK4 degrader to take on innate immunity". Nature Biotechnology. 38 (11): 1221–1223. doi:10.1038/s41587-020-0724-8. PMID 33144727. S2CID 226249972.

IRAK4 (English Wikipedia)

doi.org (Global: 2nd place; English: 2nd place)

ensembl.org (Global: 1,626th place; English: 1,007th place)